Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Other EventsItem 8.01. Other Events.
On April23, 2017, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing the enrollment of the first patient into a Phase 2 trial of AXS-05 for smoking cessation treatment, which is being conducted under a research collaboration between Duke University and Axsome Therapeutics.
The full text of the press release is filed as Exhibit99.1 hereto and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
Description |
99.1 |
Press Release dated April23, 2018. |